Black Diamond Therapeutics Inc BDTX

$1.89 +0.01 (0.53%)

Valuation

Market cap
108,588,000
Revenue TTM
$70,000,000
Net income TTM
$22,370,000
PE ratio
0.00
Forward PE
—
Profit margin
31.96%
Debt to equity
0.00

Trading

Volume
472,200
Avg volume
596,292
Day's range
$1.88 – $1.94
Shares out
57,454,000
Stochastic %K
43%
Beta
3.32
Analysts
Strong Sell
Price target
$9.06

Price

Company profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung...

Show more

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 252 0848
Website
https://www.blackdiamondtherapeutics.com
Address
245 First Street, 18th Floor, Cambridge, United States

Latest news

Stocktwits

BossTrade Oct 2, 6:41 PM
$BDTX They loading the boat. Several share types in this. All they need to do is swap algo and it gaps
0 replies
I_am_retail_investor Oct 2, 4:03 PM
$BDTX - when are the deep pockets planning to get off the bunny slope and onto the black diamond?
1 replies
BossTrade Oct 2, 2:27 PM
$BDTX Q4 in the house. Gonna pop as algos flick in anticipation of news. Not even talking about the chart and dynamic pressure under the lid
0 replies
BossTrade Oct 1, 12:34 AM
$BDTX Looks like reversal is in. Floor moving higher at 34.1%, damn nice
0 replies
superalby Sep 30, 9:43 AM
$BDTX The excellent data presented at ASCO on the phase 2 study of silevertinib had a cutoff date of April 11. Another 6 months have now passed for the patients on treatment. It would appear that the data have matured in an astonishing way. Best-in-class and unmet need. Fasten your seatbelts
1 replies
BossTrade Sep 29, 3:54 PM
$BDTX Beat up bios waking up
1 replies
BossTrade Sep 28, 6:26 PM
$BDTX Look at what happened at kod. That’s how bio works. We’ll have our day
1 replies
BossTrade Sep 28, 4:04 PM
$BDTX The bond market killing the general market with exception of some bellwethers and hyper scalers . 2/3 of SP500 in bear market Gov will be forced to intervene
1 replies